SAN FRANCISCO, June 4, 2013 /PRNewswire/ -- A new review by researchers at the
University of Maryland School of Medicine highlights a large body of published
research demonstrating how modified citrus pectin (MCP), works against cancer.
The study, which was published on April 18 in the American Journal of
Pharmacology and Toxicology, also examines MCP's synergistic relationship with
chemotherapy, as well as its ability to modulate immunity, safely remove heavy
metals and block the pro-inflammatory protein galectin-3.
"This review does an excellent job consolidating our knowledge about modified
citrus pectin's remarkable therapeutic impact," says integrative medicine
researcher and MCP co-developer, Isaac Eliaz, M.D. "In particular, it identifies
MCP's different mechanisms of action against metastatic cancer, heavy metal
toxicity and chronic, life threatening illnesses related to excess galectin-3."
The Development of Modified Citrus Pectin
While plant pectins have long been known to support digestive and immune health
through their actions in the GI tract, the main obstacle preventing them from
exerting systemic benefits throughout the body has been their bio-availability.
The long complex soluble fibers in regular pectin are simply too large to be
absorbed into the circulation. This problem was solved with the development of
MCP, which is prepared from regular citrus pectin using a modification process
to reduce the size and cross branching of the pectin molecules. The modification
allows MCP to easily absorb into the circulation and exert numerous therapeutic
effects throughout the body, now demonstrated in multiple peer reviewed studies.
For example, the review discusses MCP's ability to control metastatic melanoma,
as well as prostate, breast and colon cancers. These outcomes have been
confirmed in multiple published studies, which have also shown MCP's ability to
suppress angiogenesis (new blood vessel growth to tumors). Blocking angiogenesis
is a key factor in preventing cancer metastasis.
MCP has also been shown to induce apoptosis in cancer cells. Apoptosis, known as
programmed cell death, is suppressed in tumors, allowing them to grow
uncontrollably. Numerous studies show MCP supports apoptosis in cancer,
including a 2010 study from Columbia University which found that MCP induced
apoptosis in both androgen dependent and androgen independent prostate cancer
cells. This is particularly significant because androgen independent prostate
cancer is a highly aggressive, difficult-to-treat cancer.
Other important findings demonstrate MCP's abilities to make chemotherapy more
effective. Co-administering MCP with cisplatin, etoposide or doxorubicin makes
cancer cells more sensitive to these frontline treatments. MCP is also useful
during radiation therapy, helping to protect organs from the damaging
inflammatory effects of radiation.
Natural Galectin-3 Blocker
One of the active, "culprit" biomarkers in cancer progression is the cell
signaling protein, galectin-3. Elevated levels of this protein are directly
linked with the development, progression and metastasis of many cancers, as well
as chronic diseases related to inflammation and fibrosis. Large scale clinical
studies demonstrate the direct involvement of galectin-3 in cardiovascular
disease and heart failure, while other studies highlight its role in kidney
fibrosis, liver failure, arthritis and other pro-inflammatory diseases.
Galectin-3 is a sticky, cell surface molecule that allows cancer cells to
aggregate and metastasize. It also drives the processes of chronic inflammation
and the progression of inflammation to fibrosis within organs and tissues,
leading to organ failure. By binding to galectin-3, MCP inactivates the protein,
limiting cancer cell adhesion and reducing progression of numerous chronic
MCP has also been shown to increase immune activity against human leukemia
cells, by significantly enhancing activation of NK cells and increasing their
functionality against leukemia. Furthermore, a number of clinical trials show
MCP's abilities to safely remove heavy metals such as lead, mercury, arsenic and
others from the circulation, without affecting essential mineral levels.
These additional functions increase MCP's therapeutic value in treating and
preventing cancer and other chronic illnesses. Because of its multiple
mechanisms of action, MCP is proving to be an important adjuvant therapy against
even the most difficult, treatment-resistant cancers. With more than 12 million
cancer patients in the U.S., this is an important development.
"The more we learn about MCP, the more impressive it becomes," says Dr. Eliaz.
"With its ability to control aggressive cancers, reduce inflammation, enhance
immunity, chelate heavy metals and work synergistically with a variety of
chemotherapeutic agents, it has earned an important role within anti-cancer and
chronic disease protocols."
To learn more about MCP, visit www.modifiedcitruspectin.org.
Niture SK, Refai L. Plant Pectin: A Potential Source for Cancer Suppression.
American Journal of Pharmacology and Toxicology. 2013; 8(1):9-19.
SOURCE Better Health Publishing